您好，欢迎来到仪器设备网！ [登录] [免费注册]
仪器设备网
发布求购
位置：首页 > 产品库 > PI3K/mTOR Inhibitor-4
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
PI3K/mTOR Inhibitor-4
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
PI3K/mTOR Inhibitor-4图片
CAS NO:2361215-32-7
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
PI3K/mTOR Inhibitor-4 是一种泛 I 类 PI3K/mTOR 抑制剂，具有口服活性。PI3K/mTOR Inhibitor-4 对 PI3Kα、PI3Kγ、PI3Kδ 和 mTOR 具有酶抑制活性，IC50 值分别为 0.63 nM、22 nM、9.2 nM 和 13.85 nM。PI3K/mTOR Inhibitor-4 可用于癌症的研究。
Cas No.2361215-32-7
分子式C27H22FN3O6S
分子量535.54
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

PI3K/mTOR Inhibitor-4 is an orally active pan-class IPI3K/mTORinhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR withIC50values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer[1].

PI3K/mTOR Inhibitor-4 (compound 8d-1) has enzymatic inhibition activity for PI3Kα, PI3Kδ, mTOR, PI3Kβ and PI3Kγ with IC50values of 0.63 nM, 9.2 nM, 13.85 nM, 94.54 nM and 22 nM, respectively[1].
PI3K/mTOR Inhibitor-4 shows potent anti-proliferation activity in A549, Hela, HCT-116, HepG2, A375 and MCF-7 cells with IC50values of 1.35 nM, 1.22 nM, 13.44 nM, 1.08 nM, 18.4 nM and 8.26 nM, respectively[1].
PI3K/mTOR Inhibitor-4 (2.5-10 µM; 24 h) inhibits the PI3K/AKT/mTOR pathway[1].

Cell Viability Assay[1]

Cell Line:PC12 and LO2 cells
Concentration:0.625-20 µM
Incubation Time:72 h
Result:Showed low toxicity in concentrations from 0.625 µM to 20 µM.

Western Blot Analysis[1]

Cell Line:Hela cells
Concentration:2.5, 5 and 10 µM
Incubation Time:24 h
Result:Dose-dependently decreased the level of phosphorylation of AKT and its downstream target S6 in Hela cell line.

PI3K/mTOR Inhibitor-4 (compound 8d-1) (i.v., oral; 1mg/kg, 10 mg/kg) displays favorable pharmacokinetic parameters in Sprague-Dawley rats[1].
PI3K/mTOR Inhibitor-4 (oral; 10-50 mg/kg) shows significant efficiency in Hela/A549 tumor xenograft models without causing significant weight loss and toxicity[1].

Animal Model:SD rats (male; 200-220 g)[1]
Dosage:1, 10 mg/kg
Administration:Intravenous, oral
Result:
IV (1 mg/kg)PO (10 mg/kg)
CL (ml/min/kg)Vss (ml/kg)Tmax(h)Cmax(ng/ml)AUCinf (ng*h/ml)t1/2(h)F(%)
8.61199.812.67886.674753.351.7824.1
Animal Model:BALB/c nude mice (female; 6-7 weeks; 18-22 g)[1]
Dosage:10, 20, 40, 50 mg/kg/d (Hela model) and 20, 40 mg/kg/d (A549 model)
Administration:Oral
Result:Inhibited the growth of xenograft tumors in a dose-dependent manner.